英国治疗指导性生物标志物可及性调查
该数据集通过调查和访谈英国癌症患者及医疗专业人员,揭示了治疗指导性生物标志物检测中的主要障碍,如人员不足和报告延迟。

基本信息
资源简介
英国治疗指导性生物标志物可及性调查
【数据集背景】
本数据集源站标题为《Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals》。配套论文《Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals》发表于 Future Oncology(2025),DOI:10.1080/14796694.2025.2535098。项目资助方:This project has been developed as part of a Patient Advocacy Group Partnership between Macmillan Cancer Support and AstraZeneca UK Limited. AstraZeneca has provided funding to cover the costs associated with the project.。源站首次发布:2025-08-08。
【数据内容】
源站原始描述:To understand current barriers to treatment-guiding biomarker testing in cancer patients in the UK. A literature search, interviews with healthcare professionals, and a focus group of cancer patients were used to identify current challenges and barriers to treatment guiding biomarker testing. These were followed by online surveys of healthcare professionals and patients designed to further explore and quantify challenges to biomarker testing within the UK. Challenges were identified across the e…
【数据结构与技术规格】
文件数 6 个,合计 3.68 MB。Bell et al supplemental tables.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,53.13 KB。Supplemental Figure 1.TIF:image/tiff,453.95 KB。Supplemental figure 2.TIF:image/tiff,770.26 KB。数据集 DOI:10.6084/m9.figshare.29859225.v1。
【主题与分类】
源站学科分类:Medicine、Cell Biology、Pharmacology、Biological Sciences not elsewhere classified、Cancer、Science Policy。主题标签:Precision medicine、treatment-guiding biomarkers、cancer、patient survey、healthcare professionals、companion diagnostics。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面:https://tandf.figshare.com/articles/dataset/Access_to_treatment-guiding_biomarkers_in_the_UK_surveys_of_cancer_patients_and_healthcare_professionals/29859225
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals. Taylor & Francis. Bell, Dany; Bryce, Rachel; Delfino, Rosalia; Godin-Heymann, Nadia; Horne, Jessica; Jäger, Louise; et al
【使用注意】
· 源站最后修改于 2025-08-12,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals
- DOI:10.6084/m9.figshare.29859225.v1
- 发布日期:2025-08-08
- 文件数:6 个
- 文件总体积:3.68 MB
- 源站页面:https://tandf.figshare.com/articles/dataset/Access_to_treatment-guiding_biomarkers_in_the_UK_surveys_of_cancer_patients_and_healthcare_professionals/29859225
命令行下载
curl -L -o "Bell et al supplemental tables.docx" "https://ndownloader.figshare.com/files/57028595"
curl -L -o "Supplemental Figure 1.TIF" "https://ndownloader.figshare.com/files/57028598"
curl -L -o "Supplemental figure 2.TIF" "https://ndownloader.figshare.com/files/57028601"
curl -L -o "Supplemental figure 3.TIF" "https://ndownloader.figshare.com/files/57028604"
curl -L -o "Supplemental figure 4.TIF" "https://ndownloader.figshare.com/files/57028607"
curl -L -o "Supplemental figure 5.TIF" "https://ndownloader.figshare.com/files/57028610"
文件清单
Bell et al supplemental tables.docx(53.13 KB)Supplemental Figure 1.TIF(453.95 KB)Supplemental figure 2.TIF(770.26 KB)Supplemental figure 3.TIF(898.88 KB)Supplemental figure 4.TIF(661.63 KB)Supplemental figure 5.TIF(845.00 KB)
文件总体积 3.68 MB(源站 API 实测)。
数据说明
To understand current barriers to treatment-guiding biomarker testing in cancer patients in the UK.
A literature search, interviews with healthcare professionals, and a focus group of cancer patients were used to identify current challenges and barriers to treatment guiding biomarker testing. These were followed by online surveys of healthcare professionals and patients designed to further explore and quantify challenges to biomarker testing within the UK.
Challenges were identified across the entire biomarker testing pathway, the most common being insufficient workforce, long turnaround times, and lack of specific training. These challenges had a negative impact on patient access to targeted cancer therapies.
Challenges to accessing treatment-guiding biomarker testing of cancer patients within the UK are impacting clinical decision-making. There is a requirement to improve awareness and training of healthcare professionals, particularly nurses and advanced clinical practitioners, with opportunities to improve outdated and fragmented ordering and reporting processes. Steps should also be taken to improve the availability of plain-language information materials for patients, to promote understanding and self-advocacy.
Why did we perform this research?
To identify the best treatment options for cancer patients, it is important to test the patient’s tumor for the presence of specific genetic variants or proteins (also known as biomarkers). Previous publications have suggested that many UK patients do not receive such tests, even when NHS guidelines state they should. This research aimed to understand what proportion of patients are not getting tested, and why biomarker testing is not occurring in all patients.
What did we do?
Patients and healthcare professionals, including oncologists, nurses, and lab scientists, were interviewed and/or surveyed to identify any barriers in the NHS to treatment-guiding biomarker testing.
What were the results?
In total, 47.5% of the cancer patients stated they had not received treatment guiding-biomarker tests or were unsure if they had received such tests. NHS professionals told us that there were many challenges to imple
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.29859225.v1(source: https://tandf.figshare.com/articles/dataset/Access_to_treatment-guiding_biomarkers_in_the_UK_surveys_of_cancer_patients_and_healthcare_professionals/29859225)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




